Search Result

Isoforms Recommended:	TLR9

Results for "

TLR9

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Toll-like Receptor (TLR) (104) AIM2 (2) Antibody-Oligonucleotide Conjugates (AOCs) (1) Apoptosis (5) Bacterial (3) CXCR (1) ERK (2) HSP (1) IFNAR (4) Indoleamine 2,3-Dioxygenase (IDO) (1) Interleukin Related (13) JNK (2) MHC (1) Mitosis (1) mRNA (1) mTOR (1) MyD88 (1) NF-κB (3) NO Synthase (3) NOD-like Receptor (NLR) (1) Oligopeptide Cotransporter (1) p38 MAPK (3) PD-1/PD-L1 (1) Pyroptosis (1) Reference Standards (1) Small Interfering RNA (siRNA) (3) Sodium Channel (1) Stearoyl-CoA Desaturase (SCD) (3) TNF Receptor (6)
By Research Areas:	Cancer (28) Cardiovascular Disease (2) Infection (11) Inflammation/Immunology (91) Metabolic Disease (3) Neurological Disease (4)
Oligonucleotides:	CpG ODNs (71) Rat Pre-designed siRNA Sets (1) mRNA (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) Antisense Oligonucleotides (8) siRNAs (3)

112

Inhibitors & Agonists

Inhibitory Antibodies

Antibodies

Oligonucleotides

Targets Recommended: Toll-like Receptor (TLR)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-146245

ODN 1826 Maximum Cited Publications 10 Publications Verification CpG 1826	Toll-like Receptor (TLR) Apoptosis NO Synthase	Cardiovascular Disease Inflammation/Immunology Cancer
ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and *TLR9* agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma .

HY-134581

Enpatoran Maximum Cited Publications 16 Publications Verification M5049	Toll-like Receptor (TLR)	Inflammation/Immunology
Enpatoran (M5049) is a potent, orally active and dual *TLR7/8* inhibitor with IC₅₀s of 11.1 nM and 24.1 nM in HEK293 cells, respectively. Enpatoran is inactive against TLR3, TLR4 and TLR9. Enpatoran can block molecule synthetic ligands and natural endogenous RNA ligands. Enpatoran exhibits excellent pharmacokinetic properties in vivo. Enpatoran can be used for both innate and adaptive autoimmunity blocking research .

HY-146244

Agatolimod 1 Publications Verification ODN 2006; PF-3512676; CpG 7909; ODN 7909	Toll-like Receptor (TLR) Bacterial NO Synthase Apoptosis	Infection Cancer
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a *TLR9* agonist and immunomodulator with an EC₅₀ of 180 nM against human *TLR9. Agatolimod activates and upregulates the expression of both TLR9* and *TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19*, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .

HY-150724

ODN 1018 2 Publications Verification 1018 ISS	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 1018 (1018 ISS) is a *TLR9* agonist and immune modulator. ODN 1018 exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 triggers sustained suppression of allergic airway inflammation. ODN 1018 can be used for the research of allergic asthma and systemic lupus erythematosus .

HY-150218

Agatolimod sodium 1 Publications Verification ODN 2006 sodium; ODN 7909 sodium; PF-3512676 sodium; CpG 7909 sodium	Toll-like Receptor (TLR)	Cancer
Agatolimod sodium (ODN 2006) is a class B CpG ODN and is a *TLR9* agonist. Agatolimod sodium can be used as vaccine adjuvant. Agatolimod sodium can be used for the research of cancer. Sequence: 5’-TCGTCGTTTTGTCGTTTTGTCGTT-3’ .

HY-124603

AT791 5+ Cited Publications	Toll-like Receptor (TLR)	Inflammation/Immunology
AT791 is a potent and orally bioavailable *TLR7* and *TLR9* inhibitor. AT791 inhibits TLR7 and 9 signaling in a variety of human and mouse cell types and inhibits DNA-TLR9 interaction in vitro .

HY-150743

ODN 2395	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
ODN 2395 is a C class oligodeoxynucleotide and can be used as vaccine adjuvant. ODN 2395 is also a *TLR9* agonist. ODN 2395 can be used in the research of immunological vaccines. Sequence: 5'-tcgtcgttttcggcgc:gcgccg-3' (Note: The bases are phosphorothioate; ODN 2395 contains the partial palindromic sequence cggcgc:gcgccg) .

HY-146245C

ODN 1826 sodium Maximum Cited Publications 10 Publications Verification CpG 1826 sodium	Toll-like Receptor (TLR) Apoptosis NO Synthase	Cardiovascular Disease Inflammation/Immunology Cancer
ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and *TLR9* agonist. ODN 1826 sodium induces NO and iNOS production and enhances Apoptosis. ODN 1826 sodium enhances immune surveillance. ODN 1826 sodium increases aortic atherosclerotic plaque size. ODN 1826 sodium has antitumor activity against lung cancer, glioma and melanoma .

HY-150738

ODN 2088 3 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 2088 is a potent *TLR3, TLR7* and *TLR9* inhibitor. ODN 2088 shows no cytotoxic. ODN 2088 inhibits the release of IFN-α and IL-6 .

HY-150741

ODN 2216 1 Publications Verification	Toll-like Receptor (TLR) IFNAR Interleukin Related	Infection Inflammation/Immunology Cancer
ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a *TLR9* agonist. ODN 2216 interacts with *TLR9* in the lysosomes of CD4 ⁺ T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 ⁺ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 ⁺ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .

HY-134581A

Enpatoran hydrochloride Maximum Cited Publications 16 Publications Verification M5049 hydrochloride	Toll-like Receptor (TLR)	Inflammation/Immunology
Enpatoran (M5049) hydrochloride is a potent, orally active and dual *TLR7/8* inhibitor with IC₅₀s of 11.1 nM and 24.1 nM in HEK293 cells, respectively. Enpatoran hydrochloride is inactive against TLR3, TLR4 and TLR9. Enpatoran hydrochloride can block molecule synthetic ligands and natural endogenous RNA ligands. Enpatoran hydrochloride exhibits excellent pharmacokinetic properties in vivo. Enpatoran hydrochloride can be used for both innate and adaptive autoimmunity blocking research .

HY-12756A

E6446 dihydrochloride 5+ Cited Publications	Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD)	Metabolic Disease Inflammation/Immunology
E6446 dihydrochloride is a potent and orally acitve *TLR7* and *TLR9* antagonist, used in the research of deleterious inflammatory responses. E6446 dihydrochloride is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 dihydrochloride also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .

HY-148045

TLR9-IN-1 1 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR9-IN-1 is a potent and selective *TLR9* inhibitor with an IC₅₀ value of 7 nM for human TLR9. TLR9-IN-1 can be used for researching diseases associated with undesirable immune response .

HY-150750

ODN M362	Toll-like Receptor (TLR) Apoptosis	Inflammation/Immunology Cancer
ODN M362, a class C oligodeoxynucleotide, is a *TLR-9* agonist and can be used as a vaccine adjuvant. ODN M362 induces cancer cell apoptosis .

HY-150741C

ODN 2216 sodium 1 Publications Verification	Toll-like Receptor (TLR)	Cancer
ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a *TLR9* agonist. ODN 2216 sodium interacts with *TLR9* in the lysosomes of CD4 ⁺ T cells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4 ⁺ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 ⁺ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus .

HY-150724C

ODN 1018 sodium 2 Publications Verification 1018 ISS sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 1018 (1018 ISS) sodium is a *TLR9* agonist and immune modulator. ODN 1018 sodium exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 sodium triggers sustained suppression of allergic airway inflammation. ODN 1018 sodium can be used for the research of allergic asthma and systemic lupus erythematosus .

HY-150217

CpG ODN 10101 2 Publications Verification ODN 10101	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .

HY-150736

ODN 20844 1 Publications Verification	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
ODN 20844, a guanine-modified inhibitory oligonucleotide (INH-ODN), is a *TLR7* and *TLR9* (Toll-like receptor) inhibitor, and its parent is INH-ODN 2088. ODN 20844 disrupts TLR7- and TLR9-mediated immune cell immune responses. ODN 20844 sequence: 5'-TCCTGGCGc7GGGAAGT-3' .

HY-150726

ODN 1668 1 Publications Verification	Toll-like Receptor (TLR) Bacterial	Infection Neurological Disease Inflammation/Immunology
ODN 1668, a class B CpG ODN (oligodeoxynucleotide), is a *TLR-9* agonist. ODN 1668 has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of T cells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 induces an antimicrobial immune response via a *CaTLR9* dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ .

HY-150726C

ODN 1668 sodium 1 Publications Verification	Toll-like Receptor (TLR) Bacterial	Infection Neurological Disease Inflammation/Immunology
ODN 1668 sodium, a class B CpG ODN (oligodeoxynucleotide), is a *TLR-9* agonist. ODN 1668 sodium has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of T cells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 sodium induces an antimicrobial immune response via a *CaTLR9* dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ .

HY-178037

TLR9 antagonist 1	Toll-like Receptor (TLR) Interleukin Related TNF Receptor	Inflammation/Immunology
TLR9 antagonist 1 is a selective *hTLR9* antagonist with an IC₅₀ of 0.1 nM against *hTLR9. TLR9* antagonist 1 exhibits favorable pharmacokinetic and pharmacodynamic properties. TLR9 antagonist 1 can be used in the research of systemic lupus erythematosus .

HY-150750A

ODN M362 sodium	Toll-like Receptor (TLR) Apoptosis Interleukin Related TNF Receptor IFNAR	Inflammation/Immunology Cancer
ODN M362 sodium is a *TLR9* agonist that acts as a vaccine adjuvant. ODN M362 sodium activates mouse splenocytes, induces apoptosis in human hepatocellular carcinoma cells, upregulates proinflammatory cytokines in human hepatocellular carcinoma cells, and inhibits the proliferation of human hepatocellular carcinoma cells. ODN M362 sodium upregulates the expression of *TLR9/TLR6*, activates downstream signaling pathways via IRAK4 and IRF7, and strongly amplifies antigen-specific cellular immune responses to participate in innate immune activation. ODN M362 sodium can be used in research related to hepatocellular carcinoma and breast cancer .

HY-150217A

CpG ODN 10101 sodium 2 Publications Verification ODN 10101 sodium	Toll-like Receptor (TLR)	Infection
CpG ODN 10101 sodium, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist. CpG ODN 10101 sodium is a potent inducer of cytokine/chemokine expression ex vivo when used in combination with HH2(VQLRIRVAVIRA-NH2). CpG ODN 10101 sodium induces IFN- secretion from dendritic cells (DCs) and stimulates B-cells.CpG ODN 10101 sodium has antiviral and immunomodulatory properties that can influence chronic infection with HCV .

HY-150746

ODN 24991	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 24991, a guanine-modified inhibitory oligonucleotide (INH-ODN), is a *TLR3, TLR7* and *TLR9* (Toll-like receptor) inhibitor, and its parent is INH-ODN 2088. ODN 24991 disrupts TLR3-, TLR7- and TLR9-mediated immune cell immune responses. ODN 24991 sequence: 5'-C-C-T-G-G-C-c7rGm-G-G-G-3' .

HY-RS14600

Tlr9 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Toll-like Receptor (TLR)	Others
Tlr9 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tlr9 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tlr9 Mouse Pre-designed siRNA Set A Tlr9 Mouse Pre-designed siRNA Set A

HY-150748A

ODN D-SL01 sodium	Toll-like Receptor (TLR)	Cancer
ODN D-SL01 sodium, a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. ODN D-SL01 sodium has strong immunostimulatory activity in a variety of vertebrate species and has anticancer activity. ODN D-SL01 sequence: 5'- T-C-G-C-G-A-C-G-T-T-C-G-C-C-C-G-A-C-G-T-T-C-G-G-T-A-3' .

HY-101929

CU-CPT17e 3 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
CU-CPT17e is a potent multi-Toll-like receptor (TLR) agonist that activates *TLR3, TLR8, and TLR9*.

HY-120538

CPG-52364	Toll-like Receptor (TLR)	Inflammation/Immunology
CPG-52364 (compound 2) is a TLR9 antagonist. CPG-52364 inhibits the HEK293-hTLR9 cell with an IC₅₀ value of 4.6 nM .

HY-150738C

ODN 2088 sodium 3 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 2088 sodium is a potent *TLR3, TLR7* and *TLR9* inhibitor. ODN 2088 sodium shows no cytotoxic. ODN 2088 inhibits the release of IFN-α and IL-6 .

HY-148511

Vidutolimod CMP-001	Toll-like Receptor (TLR) IFNAR PD-1/PD-L1 Indoleamine 2,3-Dioxygenase (IDO)	Cancer
Vidutolimod (CMP-001) is a virus-like particle containing a *TLR9* activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates *TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ* and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .

HY-150736A

ODN 20844 sodium 1 Publications Verification	Toll-like Receptor (TLR)	Infection
ODN 20844 sodium, a guanine-modified inhibitory oligonucleotide (INH-ODN), is a *TLR7* and *TLR9* (Toll-like receptor) inhibitor, and its parent is INH-ODN 2088. ODN 20844 sodium disrupts TLR7- and TLR9-mediated immune cell immune responses. ODN 20844 sequence: 5'-TCCTGGCGc7GGGAAGT-3' .

HY-150746A

ODN 24991 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 24991 sodium, a guanine-modified inhibitory oligonucleotide (INH-ODN), is a *TLR3, TLR7* and *TLR9* (Toll-like receptor) inhibitor, and its parent is INH-ODN 2088. ODN 24991 sodium disrupts TLR3-, TLR7- and TLR9-mediated immune cell immune responses. ODN 24991 sequence: 5'-C-C-T-G-G-C-c7rGm-G-G-G-3' .

HY-178037A

TLR9 antagonist 1 diformate	Interleukin Related TNF Receptor Toll-like Receptor (TLR)	Inflammation/Immunology
TLR9 antagonist 1 diformate is a selective *hTLR9* antagonist with an IC₅₀ of 0.1 nM against *hTLR9. TLR9* antagonist 1 diformate exhibits favorable pharmacokinetic and pharmacodynamic properties. TLR9 antagonist 1 diformate can be used in the research of systemic lupus erythematosus .

HY-RS14599

TLR9 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Toll-like Receptor (TLR)	Others
TLR9 Human Pre-designed siRNA Set A contains three designed siRNAs for TLR9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TLR9 Human Pre-designed siRNA Set A TLR9 Human Pre-designed siRNA Set A

HY-150745A

ODN 24987 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 24987 sodium is a Guanine-modified inhibitory oligonucleotides (ODN), targeting *TLR9*. ODN 24987 can inhibit IL-6 and IFN-α release. ODN 24987 sodium can be used for research immune disorders. ODN 24987 sequence: 5’-C-C-T-G-G-C-c7G-G-G-G-3’ .

HY-150724B

FITC-labeled ODN 1018 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
FITC-labeled ODN 1018 (sodium),an oligodeoxynucleotide, is a *TLR-9* agonist. FITC-labeled ODN 1018 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-114592

M199	Toll-like Receptor (TLR) Interleukin Related TNF Receptor	Inflammation/Immunology
M199 is a potent *TLR3/TLR9* signaling inhibitor. M199 induces secretion of IL-6, IL-8 and TNFα in human PBMCs. M199 is used as a selective inducer of the immune response .

HY-150743A

Biotin-labeled ODN 2395 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
Biotin-labeled ODN 2395 (sodium), a C class oligodeoxynucleotide, is a *TLR9* agonist. Biotin-labeled ODN 2395 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-148511A

Vidutolimod sodium CMP-001 sodium	Toll-like Receptor (TLR)	Cancer
Vidutolimod sodium is a CpG-A oligodeoxynucleotide. Vidutolimod sodium is a Toll-like receptor 9 (TLR9) agonist, which activates plasmacytoid dendritic cells (pDCs) and triggers interferon alpha (IFNα) release, leading to a cascade of anti-tumor immune effects.

HY-146245F

FAM-labeled ODN 1826 sodium 1 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
FAM-labeled ODN 1826 sodium, a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. FAM-labeled ODN 1826 sodium can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy or flow cytometry.

HY-146245A

Biotin-labeled ODN 1826 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
Biotin-labeled ODN 1826 (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. Biotin-labeled ODN 1826 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-150743C

ODN 2395 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 2395 sodium is a C class oligodeoxynucleotide and can be used as vaccine adjuvant. ODN 2395 sodium is also a *TLR9* agonist. ODN 2395 sodium can be used in the research of immunological vaccines. Sequence: 5'-tcgtcgttttcggcgc:gcgccg-3' .

HY-150743B

FITC-labeled ODN 2395 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
FITC-labeled ODN 2395 (sodium), a C class oligodeoxynucleotide, is a *TLR9* agonist. FITC-labeled ODN 2395 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-150742A

ODN 2336 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 2336 sodium is a A-Class CpG ODN (oligodeoxynucleotides), is a potent *TLR9* agonist. ODN 2336 sodium induces the production of IFN-α. ODN 2336 sodium up-regulates the expression of IP-10 mRNA and IL-18 mRNA. ODN 2336 sodium can be used as adjuvant of vaccines .

HY-153840A

ODN INH 18 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN INH-18 sodium is a linear 24-mer class B INH-ODN in which the 5' INH-ODN 4084-F sequence was followed by a random stretch of 12 nucleotides lacking the ability to form significant secondary structures. ODN INH-18 sodium showes inhibitory potency for TLR9 ligand-induced IFN-α production.

HY-150212

Tilsotolimod IMO-2125	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
Tilsotolimod (IMO-2125) is a *TLR9* agonist. Tilsotolimod activates the *TLR9* signaling pathway, triggers downstream pro-inflammatory and immunostimulatory pathways, enhances the uptake and killing of cancer cells, and induces adaptive immune responses. Tilsotolimod is applicable to research related to melanoma and colorectal cancer .

HY-150212A

Tilsotolimod sodium IMO-2125 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
Tilsotolimod (IMO-2125) sodium is a *TLR9* agonist. Tilsotolimod sodium activates the *TLR9* signaling pathway, triggers downstream pro-inflammatory and immunostimulatory pathways, enhances the uptake and killing of cancer cells, and induces adaptive immune responses. Tilsotolimod sodium is applicable to research related to melanoma and colorectal cancer .

HY-150739A

ODN 21158 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 21158 sodium is a potent G-modified *TLR3* and *TLR9* inhibitor. ODN 21158 sodium inhibits IFN-α secretion in a dose dependent manner .

HY-150739

ODN 21158	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 21158 is a potent G-modified *TLR3* and *TLR9* inhibitor. ODN 21158 shows no cytotoxic. ODN 21158 inhibits IFN-α secretion in a dose dependent manner .

HY-146244A

Biotin-labeled agatolimod sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
Biotin-labeled agatolimod (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. Biotin-labeled agatolimod (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

Cat. No.	Product Name	Target	Research Area	Image

HY-P991257

MK-1966 1 Publications Verification	Interleukin Related CXCR MHC	Cancer
MK-1966 is an anti-IL-10 antibody. MK-1966 inhibits secretion of cytokines from activated macrophages, production of CC and CXC chemokines, and a TH1 response, down-regulates MHC and costimulatory molecules on dendritic cells (DCs), and induces regulatory T cells. MK-1966 can be used for the research of cancer , such as gastric cancer .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83576

	Toll-Like Receptor 9 Antibody (YA3321) Toll-Like Receptor 9; CD289; TLR9; Toll like receptor 9; Toll like receptor 9 isoform A precursor; Toll like receptor 9 isoform B	WB	Human
	Toll-Like Receptor 9 Antibody (YA3321) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Toll-Like Receptor 9.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification